Shiru and Ingredion Announce Global R&D Collaboration
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy INGR?
Source: Globenewswire
- Collaboration Launch: Shiru and Ingredion have announced a global R&D collaboration aimed at accelerating the discovery and commercialization of novel functional proteins, leveraging Shiru's AI platform that has analyzed over 77 million natural protein sequences, significantly enhancing R&D efficiency.
- Market Demand Response: The partnership focuses on developing next-generation prebiotics derived from natural sources to promote healthier microbiomes, addressing consumer demand for clinically credible and manufacturable ingredients, directly responding to market pressures.
- Wide Customer Reach: Ingredients developed through this joint research will be directed to Ingredion's 18,000+ customers across 120 countries, ensuring that new products can quickly enter the market and enhance customer competitiveness.
- Innovation-Driven Technology: Shiru's AI technology reduces ingredient discovery time from years to months, and combined with Ingredion's market scale and customer relationships, creates a direct path from discovery to market, driving innovation and development in the food industry.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy INGR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on INGR
Wall Street analysts forecast INGR stock price to rise
4 Analyst Rating
1 Buy
3 Hold
0 Sell
Hold
Current: 113.110
Low
119.00
Averages
125.50
High
136.00
Current: 113.110
Low
119.00
Averages
125.50
High
136.00
About INGR
Ingredion Incorporated is a global ingredient solutions provider serving customers in nearly 120 countries. The Company turns grains, fruits, vegetables and other plant-based materials into value-added ingredient solutions for the food, beverage, animal nutrition, brewing and industrial markets. Its segments include Texture & Healthful Solutions (T&HS), Food & Industrial Ingredients - Latin America (F&II - LATAM) and Food & Industrial Ingredients - U.S./Canada (F&II - U.S./Canada). Its product lines include starches and sweeteners, animal feed products and edible corn oil. Its starch-based products include both food-grade and industrial starches, as well as biomaterials and non-GMO (genetically modified organism) products. Its sweetener products include glucose syrups, high maltose syrups, high fructose corn syrup, caramel color, dextrose, polyols, maltodextrins, glucose and syrup solids, high-intensity sweeteners, and various non-GMO products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Shiru and Ingredion Announce Global R&D Collaboration
- Collaboration Launch: Shiru and Ingredion have announced a global R&D collaboration aimed at accelerating the discovery and commercialization of novel functional proteins, leveraging Shiru's AI platform that has analyzed over 77 million natural protein sequences, significantly enhancing R&D efficiency.
- Market Demand Response: The partnership focuses on developing next-generation prebiotics derived from natural sources to promote healthier microbiomes, addressing consumer demand for clinically credible and manufacturable ingredients, directly responding to market pressures.
- Wide Customer Reach: Ingredients developed through this joint research will be directed to Ingredion's 18,000+ customers across 120 countries, ensuring that new products can quickly enter the market and enhance customer competitiveness.
- Innovation-Driven Technology: Shiru's AI technology reduces ingredient discovery time from years to months, and combined with Ingredion's market scale and customer relationships, creates a direct path from discovery to market, driving innovation and development in the food industry.
See More
Ingredion CEO James P. Zallie Sells Shares Amid Earnings Concerns
- Share Sale Details: On February 18, 2026, James P. Zallie sold 9,958 shares of Ingredion for approximately $1.16 million, reducing his direct holdings by 23.2% to 33,010 shares, indicating a cautious outlook on the company's future.
- Management Changes: Zallie was appointed Chairman of the Board on February 11, 2026, which may raise investor concerns about governance; however, his share sale was part of a Rule 10b5-1 trading plan, alleviating some worries.
- Lackluster Financial Performance: Despite year-over-year growth in net income and EPS for Q4 of fiscal 2025, Ingredion experienced a revenue decline and has posted three consecutive quarters of declining net income and EPS, highlighting challenges in recovery from global production impacts.
- Investment Considerations: Investors should note that The Motley Fool's analyst team did not include Ingredion in their current top ten stock recommendations, suggesting a cautious market sentiment regarding its future performance, warranting careful risk assessment before investing.
See More
Ingredion CEO Sells Nearly 10,000 Shares in Open Market Transaction
- Executive Share Reduction: James P. Zallie, CEO of Ingredion, sold 9,958 shares on February 18, 2026, for $1.16 million, reducing his direct holdings to 33,010 shares, which may raise concerns about his confidence in the company's future prospects.
- Ownership Percentage Shift: Zallie's direct ownership decreased from 42,968 shares to 33,010 shares, representing 0.0520% of the company's outstanding shares, prompting investor scrutiny regarding his future decisions, although he has no reported indirect or derivative positions.
- Compliance with Trading Plan: The sale was executed under a pre-established Rule 10b5-1 trading plan, aligning with Zallie's recent trading patterns, indicating that the reduction is not necessarily a negative signal about the company's outlook, urging investors to remain rational.
- Financial Performance Concerns: While Zallie's net income and earnings per share grew year-over-year, Ingredion's revenue declined in Q4 of fiscal year 2025, marking the third consecutive quarter of declining net income and EPS, highlighting ongoing recovery challenges from global production impacts that investors should monitor.
See More
Univar Solutions Partners with Ingredion for Pharmaceutical Distribution
- Strategic Partnership: Univar Solutions has entered into an exclusive distribution agreement with Ingredion Pharma Solutions, positioning itself as the sole distributor of Ingredion's global pharmaceuticals portfolio in the U.S. and Canada, thereby solidifying its market presence in the pharmaceutical sector.
- Portfolio Expansion: This collaboration allows Univar to enhance its pharmaceutical and nutraceutical ingredient offerings, incorporating a wide range of functional excipients such as direct compression and wet granulation binders, fillers for tablets and capsules, and more, which strengthens its competitive edge.
- Market Coverage Enhancement: By becoming the exclusive distributor of pharmaceutical starches in the U.S. and Canada, Univar not only broadens its market reach but also improves its service capabilities to pharmaceutical manufacturers, addressing the growing market demand effectively.
- Increased Industry Influence: This partnership significantly boosts Univar's influence in the pharmaceutical and nutraceutical sectors, leveraging Ingredion's expertise and extensive distribution network to drive growth in the rapidly evolving pharmaceutical market.
See More
Univar Solutions Partners Exclusively with Ingredion for Pharma Distribution
- Exclusive Distribution Agreement: Univar Solutions' Ingredients + Specialties division has been appointed as the exclusive distributor for Ingredion Pharma Solutions, responsible for distributing its global pharmaceuticals portfolio in the U.S. and Canada, which is expected to significantly enhance market share and customer base.
- Expanded Product Range: This partnership allows Univar to offer a variety of functional excipients, including direct compression and wet granulation binders, and fillers for tablets and capsules, thereby assisting pharmaceutical and nutraceutical customers in overcoming formulation challenges and driving business growth.
- Market Demand Response: The global senior vice president of Health & Nutrition at Univar stated that this agreement will expand access to pharmaceutical starches and other functional excipients, meeting customer demands for high-quality ingredients and further solidifying its leadership position in the industry.
- Technical Support and Innovation: Univar Solutions is committed to leveraging its robust technical support and formulation expertise to help customers navigate the rapidly changing future of the industry, ensuring competitiveness and innovation in the market.
See More
Ingredion CEO Sells Shares Amidst Earnings Concerns
- Executive Share Sale: James P. Zallie, President and CEO of Ingredion, sold 33,597 shares on February 11, 2026, for approximately $4.02 million, representing 40.11% of his direct holdings, reducing his ownership to 50,166 shares, indicating a cautious outlook on the company's future.
- Transaction Context: The share sale was part of a Rule 10b5-1 trading plan as reported in SEC Form 4, and while such insider sales are common, they may raise investor concerns about the company's prospects, especially given the backdrop of declining earnings.
- Financial Performance Issues: Ingredion's Q4 earnings report for fiscal year 2025 revealed that while net income and earnings per share grew year-over-year, revenue declined, marking the third consecutive quarter of falling net income and EPS, highlighting the slow recovery from global production impacts.
- Investor Considerations: Although Zallie's sale should not overly alarm investors, analysts noted that Ingredion did not make the list of top investment stocks, suggesting that potential buyers should exercise caution, particularly in light of the company's ongoing performance challenges.
See More
Shiru and Ingredion Announce Global R&D Collaboration
- Collaboration Launch: Shiru and Ingredion have announced a global R&D collaboration aimed at accelerating the discovery and commercialization of novel functional proteins, leveraging Shiru's AI platform that has analyzed over 77 million natural protein sequences, significantly enhancing R&D efficiency.
- Market Demand Response: The partnership focuses on developing next-generation prebiotics derived from natural sources to promote healthier microbiomes, addressing consumer demand for clinically credible and manufacturable ingredients, directly responding to market pressures.
- Wide Customer Reach: Ingredients developed through this joint research will be directed to Ingredion's 18,000+ customers across 120 countries, ensuring that new products can quickly enter the market and enhance customer competitiveness.
- Innovation-Driven Technology: Shiru's AI technology reduces ingredient discovery time from years to months, and combined with Ingredion's market scale and customer relationships, creates a direct path from discovery to market, driving innovation and development in the food industry.
See More
Ingredion CEO James P. Zallie Sells Shares Amid Earnings Concerns
- Share Sale Details: On February 18, 2026, James P. Zallie sold 9,958 shares of Ingredion for approximately $1.16 million, reducing his direct holdings by 23.2% to 33,010 shares, indicating a cautious outlook on the company's future.
- Management Changes: Zallie was appointed Chairman of the Board on February 11, 2026, which may raise investor concerns about governance; however, his share sale was part of a Rule 10b5-1 trading plan, alleviating some worries.
- Lackluster Financial Performance: Despite year-over-year growth in net income and EPS for Q4 of fiscal 2025, Ingredion experienced a revenue decline and has posted three consecutive quarters of declining net income and EPS, highlighting challenges in recovery from global production impacts.
- Investment Considerations: Investors should note that The Motley Fool's analyst team did not include Ingredion in their current top ten stock recommendations, suggesting a cautious market sentiment regarding its future performance, warranting careful risk assessment before investing.
See More
Ingredion CEO Sells Nearly 10,000 Shares in Open Market Transaction
- Executive Share Reduction: James P. Zallie, CEO of Ingredion, sold 9,958 shares on February 18, 2026, for $1.16 million, reducing his direct holdings to 33,010 shares, which may raise concerns about his confidence in the company's future prospects.
- Ownership Percentage Shift: Zallie's direct ownership decreased from 42,968 shares to 33,010 shares, representing 0.0520% of the company's outstanding shares, prompting investor scrutiny regarding his future decisions, although he has no reported indirect or derivative positions.
- Compliance with Trading Plan: The sale was executed under a pre-established Rule 10b5-1 trading plan, aligning with Zallie's recent trading patterns, indicating that the reduction is not necessarily a negative signal about the company's outlook, urging investors to remain rational.
- Financial Performance Concerns: While Zallie's net income and earnings per share grew year-over-year, Ingredion's revenue declined in Q4 of fiscal year 2025, marking the third consecutive quarter of declining net income and EPS, highlighting ongoing recovery challenges from global production impacts that investors should monitor.
See More
Univar Solutions Partners with Ingredion for Pharmaceutical Distribution
- Strategic Partnership: Univar Solutions has entered into an exclusive distribution agreement with Ingredion Pharma Solutions, positioning itself as the sole distributor of Ingredion's global pharmaceuticals portfolio in the U.S. and Canada, thereby solidifying its market presence in the pharmaceutical sector.
- Portfolio Expansion: This collaboration allows Univar to enhance its pharmaceutical and nutraceutical ingredient offerings, incorporating a wide range of functional excipients such as direct compression and wet granulation binders, fillers for tablets and capsules, and more, which strengthens its competitive edge.
- Market Coverage Enhancement: By becoming the exclusive distributor of pharmaceutical starches in the U.S. and Canada, Univar not only broadens its market reach but also improves its service capabilities to pharmaceutical manufacturers, addressing the growing market demand effectively.
- Increased Industry Influence: This partnership significantly boosts Univar's influence in the pharmaceutical and nutraceutical sectors, leveraging Ingredion's expertise and extensive distribution network to drive growth in the rapidly evolving pharmaceutical market.
See More
Univar Solutions Partners Exclusively with Ingredion for Pharma Distribution
- Exclusive Distribution Agreement: Univar Solutions' Ingredients + Specialties division has been appointed as the exclusive distributor for Ingredion Pharma Solutions, responsible for distributing its global pharmaceuticals portfolio in the U.S. and Canada, which is expected to significantly enhance market share and customer base.
- Expanded Product Range: This partnership allows Univar to offer a variety of functional excipients, including direct compression and wet granulation binders, and fillers for tablets and capsules, thereby assisting pharmaceutical and nutraceutical customers in overcoming formulation challenges and driving business growth.
- Market Demand Response: The global senior vice president of Health & Nutrition at Univar stated that this agreement will expand access to pharmaceutical starches and other functional excipients, meeting customer demands for high-quality ingredients and further solidifying its leadership position in the industry.
- Technical Support and Innovation: Univar Solutions is committed to leveraging its robust technical support and formulation expertise to help customers navigate the rapidly changing future of the industry, ensuring competitiveness and innovation in the market.
See More
Ingredion CEO Sells Shares Amidst Earnings Concerns
- Executive Share Sale: James P. Zallie, President and CEO of Ingredion, sold 33,597 shares on February 11, 2026, for approximately $4.02 million, representing 40.11% of his direct holdings, reducing his ownership to 50,166 shares, indicating a cautious outlook on the company's future.
- Transaction Context: The share sale was part of a Rule 10b5-1 trading plan as reported in SEC Form 4, and while such insider sales are common, they may raise investor concerns about the company's prospects, especially given the backdrop of declining earnings.
- Financial Performance Issues: Ingredion's Q4 earnings report for fiscal year 2025 revealed that while net income and earnings per share grew year-over-year, revenue declined, marking the third consecutive quarter of falling net income and EPS, highlighting the slow recovery from global production impacts.
- Investor Considerations: Although Zallie's sale should not overly alarm investors, analysts noted that Ingredion did not make the list of top investment stocks, suggesting that potential buyers should exercise caution, particularly in light of the company's ongoing performance challenges.
See More
